The role of maintenance therapy in multiple myeloma

Lipe, Brea; Vukas, Rachel; Mıkhael, Joseph

doi:10.1038/bcj.2016.89

Cited by 29 publications

(29 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of cases was extracted, and age-adjusted specific rates were calculated for two age-groups (40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59) and 60+) and to all ages. The age-adjusted specific rates were calculated using the world standard population, according to sex and for selected geographic areas with available data.…”

Section: Methodsmentioning

confidence: 99%

Epidemiology of multiple myeloma in 17 Latin American countries: an update

et al. 2018

View full text Add to dashboard Cite

The objective of this study was to describe incidence, mortality rates, and trends for multiple myeloma (MM) in Latin America (LA), contributing to better knowledge on the epidemiology of MM in this continent. Incidence data were extracted from the International Agency for Research on Cancer (IARC), for the period 1990–2007. Mortality data were obtained for 17 countries from the World Health Organization, for the period 1995–2013. Annual average percentage change (AAPC) and 95% confidence interval (95% CI) were calculated for incidence and mortality. The average incidence rate of MM was higher in Cali (Colombia). For the age‐group over 60 years old, rates were 14.2 and 12.8 per 100,000 inhabitants for men and women, respectively. Increasing incidence trends were verified for Cali (Colombia). Mortality rates were higher among men; most countries presented increasing trends, and the highest increments were observed in Guatemala (12.5% [95% CI: 10.6; 14.5] in men; 8.8% [95% CI: 7.8; 9.8] in women), Ecuador (5.5% [95% CI: 5.0; 6.0] in men; 3.7 [95% CI: 3.1; 4.3] in women), Paraguay (2.9% [95% CI: 2.3; 3.5] in men; 3.2% [95% CI: 2.1; 4.3] in women), and Brazil (1.4% [95% CI: 1.3; 1.5] in men; 0.9% [95% CI: 0.8; 1.0] in women). Multiple myeloma presented heterogeneous incidence patterns in Cali (Colombia), Quito (Ecuador), and Costa Rica. Increasing mortality trends were verified for most Latin American countries and could be related to limited access to diagnosis and new therapies.

show abstract

Section: Methodsmentioning

confidence: 99%

Epidemiology of multiple myeloma in 17 Latin American countries: an update

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The model assumed that maintenance therapy would extend the period during which patients would remain EP or UEP, based on evidence from clinical trials demonstrating improvements concerning remission and HRQoL post-ASCT. [10][11][12][20][21][22] Although other therapies such as ixazomib have been studied as maintenance therapy in this population, 28 data from lenalidomide studies were used for estimating the impact of maintenance therapy on productivity as lenalidomide is the currently approved standard maintenance therapy in this setting. 2 per patient, which are lower than the productivity losses found in our study.…”

Section: Discussionmentioning

confidence: 99%

“…Based on clinical evidence, the model assumed the rate of disease progression could be altered by patients receiving a maintenance therapy . Productivity losses for the population cohort were estimated for patients with NDMM not receiving maintenance therapy and compared with those receiving lenalidomide.…”

Section: Methodsmentioning

confidence: 99%

“…19 Based on clinical evidence, the model assumed the rate of disease progression could be altered by patients receiving a maintenance therapy. 2,7,[10][11][12] Productivity losses for the population cohort were estimated for patients with NDMM not receiving maintenance therapy and compared with those receiving lenalidomide. Lenalidomide maintenance therapy was used to inform the survival curve modelling, as it is the only maintenance therapy licensed in the EU5 countries.…”

Section: Endpointsmentioning

confidence: 99%

See 1 more Smart Citation

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy

Jackson

Galinsky

Alderson

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

Objective This study examined productivity losses in European patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplantation (ASCT), to better understand and model the impact of NDMM and lenalidomide maintenance therapy on productivity from a patient and societal perspective. Methods A cross‐sectional online patient survey was conducted across the UK, Germany, France, Spain and Italy. A partitioned survival model was used to estimate productivity loss and the impact of maintenance therapy, using human capital (HC) and friction cost approaches. Results Of the 115 eligible survey respondents, 76.5% were economically active at the time of diagnosis and highlighted return to work as an important factor affecting their quality of life; only 39.1% of respondents were economically active post‐ASCT. HC analyses estimated average total productivity losses per ASCT patient at EUR 290,601 over a 20‐year period. Modelling the impact of maintenance therapy alone for these patients reduced average productivity losses by just over 10%. Conclusion Patients with NDMM aspire to engage in productive lives post‐ASCT, but most are unable to do so. Access to treatments extending remission and supporting engagement in a productive life can have a positive impact both for patients and wider society.

show abstract

“…2,3 Because maintenance therapies for MM are intended for administration over a long period, potentially for many years, their tolerability, toxicity and impact on health-related quality of life (HRQoL) are important factors to consider in treatment decision making. 3 In clinical practice, the most commonly administered post-ASCT MT is the immunomodulator lenalidomide, which is the only agent approved for this use, followed by the proteasome inhibitor bortezomib (used off label in this setting). [4][5][6] Lenalidomide is associated with adverse events (AEs) including cytopenia, secondary malignancy, and dermatologic and gastrointestinal toxicities, 5 whereas bortezomib is associated with peripheral neuropathy.…”

Section: Introductionmentioning

confidence: 99%

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Schjesvold

Goldschmidt

Maisnar

et al. 2020

European J of Haematology

View full text Add to dashboard Cite

Objectives:Health-related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma post-transplant, when disease symptoms are limited. Methods:We assessed HRQoL in patients randomised to 26 cycles of MT (ixazomib vs placebo) in TOURMALINE-MM3 (NCT02181413). Results:The characteristics at study entry were well-balanced between ixazomib (n = 386) and placebo (n = 251) arms. At study entry, EORTC QLQ-C30 and MY20 scores were high for functional scales and low for symptom scales and were comparable with those of the general population. Changes in subscale scores across intervals, analysed over 30 four-week intervals using a linear mixed-effects model, were generally small and similar between arms for the EORTC QLQ-C30 Global Health Status/QoL, Physical Functioning, and Pain subscales and EORTC QLQ-MY20This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

The role of maintenance therapy in multiple myeloma

Cited by 29 publications

References 46 publications

Epidemiology of multiple myeloma in 17 Latin American countries: an update

Epidemiology of multiple myeloma in 17 Latin American countries: an update

Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial

Contact Info

Product

Resources

About